These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 26581312

  • 1. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
    Klimek L, Bousquet J, Price D.
    Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
    [Abstract] [Full Text] [Related]

  • 2. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U.
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [Abstract] [Full Text] [Related]

  • 3. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
    Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W.
    Allergy Asthma Proc; 2012 Apr; 33(4):324-32. PubMed ID: 22856633
    [Abstract] [Full Text] [Related]

  • 4. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J.
    Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
    Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC, Wahn U, Bousquet J.
    Allergy Asthma Proc; 2015 Jul; 36(1):40-7. PubMed ID: 25562555
    [Abstract] [Full Text] [Related]

  • 6. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
    Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S.
    J Allergy Clin Immunol Pract; 2014 Jul; 2(2):179-85. PubMed ID: 24607046
    [Abstract] [Full Text] [Related]

  • 7. MP29-02: a breakthrough for the treatment of allergic rhinitis.
    Bernstein JA.
    Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840
    [Abstract] [Full Text] [Related]

  • 8. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
    Ridolo E, Montagni M, Melli V, Bonzano L, Incorvaia C, Canonica GW.
    Ther Deliv; 2015 Oct; 6(6):653-9. PubMed ID: 25913181
    [Abstract] [Full Text] [Related]

  • 9. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J.
    J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
    [Abstract] [Full Text] [Related]

  • 10. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J.
    Int Arch Allergy Immunol; 2013 May; 161(4):369-77. PubMed ID: 23652808
    [Abstract] [Full Text] [Related]

  • 11. Intranasal spray medications for maintenance therapy of allergic rhinitis.
    Berger WE, Meltzer EO.
    Am J Rhinol Allergy; 2015 May; 29(4):273-82. PubMed ID: 26132312
    [Abstract] [Full Text] [Related]

  • 12. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
    Derendorf H, Meltzer EO, Hermann R, Canonica GW.
    Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
    [Abstract] [Full Text] [Related]

  • 13. Azelastine and fluticasone nasal spray: any advantage?
    Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481
    [Abstract] [Full Text] [Related]

  • 14. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
    Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, Carr W, Hellings P, Munzel U, Scadding G, Lieberman P.
    J Investig Allergol Clin Immunol; 2013 Feb; 23(7):495-503. PubMed ID: 24654314
    [Abstract] [Full Text] [Related]

  • 15. MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety.
    Berger WE.
    Expert Rev Clin Immunol; 2013 Sep; 9(9):803-11. PubMed ID: 24070043
    [Abstract] [Full Text] [Related]

  • 16. Escaping the trap of allergic rhinitis.
    Rossi O, Massaro I, Caminati M, Quecchia C, Fassio F, Heffler E, Canonica GW.
    Clin Mol Allergy; 2015 Sep; 13(1):17. PubMed ID: 26244040
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
    Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H.
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486
    [Abstract] [Full Text] [Related]

  • 18. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
    Scadding G, Price D, El-Shanawany T, Ahmed S, Ray J, Sargur R, Kumar N.
    BMJ Open; 2017 Apr 24; 7(4):e014777. PubMed ID: 28442578
    [No Abstract] [Full Text] [Related]

  • 19. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.
    Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H.
    Ann Allergy Asthma Immunol; 2010 Aug 24; 105(2):168-73. PubMed ID: 20674829
    [Abstract] [Full Text] [Related]

  • 20. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review.
    Klimek L, Berger WE, Bousquet J, Keith PK, Smith P, Sole D, Scadding G, Kuhl HC, Nguyen DT, Kopietz F, Koltun A.
    Int Arch Allergy Immunol; 2021 Aug 24; 182(11):1026-1035. PubMed ID: 34082425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.